|
|
Blood, 15 August 2006, Vol. 108, No. 4, pp. 1183-1188.
Prepublished online as a Blood First Edition Paper on April 25, 2006; DOI 10.1182/blood-2006-02-004812.
 Previous Article | Table of Contents | Next Article 
GENE THERAPY
Correction of sickle cell disease by homologous recombination in embryonic stem cells
Li-Chen Wu,
Chiao-Wang Sun,
Thomas M. Ryan,
Kevin M. Pawlik,
Jinxiang Ren, and
Tim M. Townes
From the Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Schools of Medicine and Dentistry.
Previous studies have demonstrated that sickle cell disease (SCD) can be corrected in mouse models by transduction of hematopoietic stem cells with lentiviral vectors containing antisickling globin genes followed by transplantation of these cells into syngeneic recipients. Although self-inactivating (SIN) lentiviral vectors with or without insulator elements should provide a safe and effective treatment in humans, some concerns about insertional mutagenesis persist. An ideal correction would involve replacement of the sickle globin gene ( S) with a normal copy of the gene (A). We recently derived embryonic stem (ES) cells from a novel knock-in mouse model of SCD and tested a protocol for correcting the sickle mutation by homologous recombination. In this paper, we demonstrate the replacement of the human S-globin gene with a human A-globin gene and the derivation of mice from these cells. The animals produce high levels of normal human hemoglobin (HbA) and the pathology associated with SCD is corrected. Hematologic values are restored to normal levels and organ pathology is ameliorated. These experiments provide a foundation for similar studies in human ES cells derived from sickle cell patients. Although efficient methods for production of human ES cells by somatic nuclear transfer must be developed, the data in this paper demonstrate that sickle cell disease can be corrected without the risk of insertional mutagenesis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Huo, S. C. McConnell, and T. M. Ryan
Preclinical transfusion-dependent humanized mouse model of {beta} thalassemia major
Blood,
May 7, 2009;
113(19):
4763 - 4770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Huo, S. C. McConnell, S.-R. Liu, R. Yang, T.-T. Zhang, C.-W. Sun, L.-C. Wu, and T. M. Ryan
Humanized Mouse Model of Cooley's Anemia
J. Biol. Chem.,
February 20, 2009;
284(8):
4889 - 4896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Kohn and F. Candotti
Gene Therapy Fulfilling Its Promise
N. Engl. J. Med.,
January 29, 2009;
360(5):
518 - 521.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Townes
Gene Replacement Therapy for Sickle Cell Disease and Other Blood Disorders
Hematology,
January 1, 2008;
2008(1):
193 - 196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hanna, M. Wernig, S. Markoulaki, C.-W. Sun, A. Meissner, J. P. Cassady, C. Beard, T. Brambrink, L.-C. Wu, T. M. Townes, et al.
Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin
Science,
December 21, 2007;
318(5858):
1920 - 1923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
